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Background: Obesity is strongly associated with major depressive disorder (MDD) and various other diseases.
Genome-wide association studies have identified multiple risk loci robustly associated with body mass index (BMI).
In this study, we aimed to investigate whether a genetic risk score (GRS) combining multiple BMI risk loci might
have utility in prediction of obesity in patients with MDD.
Methods: Linear and logistic regression models were conducted to predict BMI and obesity, respectively, in three
independent large case–control studies of major depression (Radiant, GSK-Munich, PsyCoLaus). The analyses were
first performed in the whole sample and then separately in depressed cases and controls. An unweighted GRS was
calculated by summation of the number of risk alleles. A weighted GRS was calculated as the sum of risk alleles at
each locus multiplied by their effect sizes. Receiver operating characteristic (ROC) analysis was used to compare the
discriminatory ability of predictors of obesity.
(Continued on next page)* Correspondence: margarita.rivera_sanchez@kcl.ac.uk
1MRC SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s
College London Box PO82, De Crespigny Park, Denmark Hill London SE5 8AF,
UK
3National Institute for Health Research Biomedical Research Centre for
Mental Health at the Maudsley and Institute of Psychiatry, King’s College
London London, UK
Full list of author information is available at the end of the article
© 2015 Hung et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Hung et al. BMC Medicine  (2015) 13:86 Page 2 of 10(Continued from previous page)
Results: In the discovery phase, a total of 2,521 participants (1,895 depressed patients and 626 controls) were
included from the Radiant study. Both unweighted and weighted GRS were highly associated with BMI (P <0.001)
but explained only a modest amount of variance. Adding ‘traditional’ risk factors to GRS significantly improved the
predictive ability with the area under the curve (AUC) in the ROC analysis, increasing from 0.58 to 0.66 (95% CI,
0.62–0.68; χ2 = 27.68; P <0.0001). Although there was no formal evidence of interaction between depression status
and GRS, there was further improvement in AUC in the ROC analysis when depression status was added to the
model (AUC = 0.71; 95% CI, 0.68–0.73; χ2 = 28.64; P <0.0001). We further found that the GRS accounted for more
variance of BMI in depressed patients than in healthy controls. Again, GRS discriminated obesity better in depressed
patients compared to healthy controls. We later replicated these analyses in two independent samples (GSK-Munich
and PsyCoLaus) and found similar results.
Conclusions: A GRS proved to be a highly significant predictor of obesity in people with MDD but accounted for
only modest amount of variance. Nevertheless, as more risk loci are identified, combining a GRS approach with
information on non-genetic risk factors could become a useful strategy in identifying MDD patients at higher risk of
developing obesity.
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Obesity is a serious public health problem associated
with an increased risk of various chronic diseases such
as hypertension, diabetes, and cardiovascular disease [1].
It is estimated that over one-third of adults in the US
are obese, whereas another one-third are overweight [2].
Moreover, the prevalence rate of obesity or overweight
in most countries has been rising steadily over the past
decades, resulting in a huge health burden [3]. There is
also evidence that people with major depressive disorder
(MDD) are more likely to be overweight or obese com-
pared to psychiatrically-healthy controls [4], particularly
in individuals with atypical depression, in whom in-
creased appetite and weight gain are more prevalent. In
addition, depressed people have a higher risk for various
medical diseases and most of them are obesity-related. A
recent meta-analysis further suggested the bi-directional
relationship between obesity and MDD [5]. Given the
high prevalence rate of both obesity and MDD, under-
standing the nature of their relationship is a pressing
clinical problem.
Dietary factors and a lack of exercise as well as genetic
factors contribute to the development of obesity. Twin
and family studies have suggested the heritability of body
mass index (BMI) to be between 0.4 and 0.7 [6]. The ad-
vance of genome-wide association studies (GWAS) has
successfully identified multiple polymorphisms associ-
ated with the risk of obesity and higher BMI [7-9].
Among them, the fat mass and obesity associated (FTO)
gene was consistently and reliably replicated in different
studies. Our team has found that several polymorphisms
in the FTO gene, the locus conferring the highest genetic
risk contribution to obesity, are associated with in-
creased BMI in people with MDD. A disease history of
depression further moderates the effect of FTO on BMI[10]. However, each risk variant only confers a modest
effect on the risk, resulting in a limited ability for obesity
prediction by applying single variants. It has been sug-
gested that combining multiple loci into a genetic risk
score (GRS) might improve prediction of obesity. Al-
though several studies have examined the joint genetic
effect using different numbers of genetic variants to dis-
criminate obesity in the general population [11-13], no
study, to date, has investigated the combined genetic ef-
fects on obesity in people with MDD.
In this study, we aimed to investigate whether a GRS
incorporating a number of well-defined common single
nucleotide polymorphisms (SNPs) might have utility in
prediction of obesity in patients with MDD.
Methods
Subjects and phenotypes
Discovery phase – Radiant study
A total of 3,244 participants (2,434 depressed patients
and 810 healthy controls) were recruited from the Radi-
ant study, which included the Depression Network
(DeNT) study [14], the Depression Case–Control
(DeCC) study [15], and the Genome-Based Therapeutic
Drugs for Depression (GENDEP) study [16]. The DeNT
study is a family study which recruited sibling pairs af-
fected with recurrent unipolar depression from eight
clinical sites across Europe and one in the USA. Only
one proband from each family was recruited in our ana-
lysis. The DeCC study is a case–control study which re-
cruited unrelated patients from three sites in the UK. All
participants in the DeNT and DeCC studies experienced
two or more episodes of major depression of at least
moderate severity. The GENDEP study recruited individ-
uals with at least one episode of depression of at least
moderate severity from nine European centres. People
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ence, substance-induced mood disorder, schizophrenia, or
bipolar disorder were excluded. The diagnosis of MDD
was ascertained using the Schedules for Clinical Assess-
ment in Neuropsychiatry (SCAN) [17] interview in all
three studies. The controls were screened for lifetime ab-
sence of any psychiatric disorder using a modified version
of the Past History Schedule [18]. Participants were ex-
cluded if they, or a first-degree relative, ever fulfilled the
criteria for depression, bipolar disorder, or schizophrenia.
Self-reported weight and height were obtained during
the SCAN interview for the individuals with depression
and during telephone interview for controls. BMI was
defined as weight in kilograms divided by height in me-
ters squared. Obesity was defined as BMI ≥30 and nor-
mal weight was defined as BMI between 18.5 and 25.
The reliability of self-report of height and weight was
assessed in the GENDEP dataset (n = 811) where we also
had measured height and weight. The correlations for
measured versus self-reported height, weight, and BMI
were 0.97, 0.95, and 0.95, respectively.
All participants were of white European ancestry. Ap-
proval was obtained from the local research ethics commit-
tees/institutional research boards of all of the participating
sites. The full list of ethics committees can be seen in
Additional file 1.
Replication phase – GSK-Munich study
Overall, 1,679 participants (822 cases and 857 controls)
were recruited at the Max-Planck Institute of Psychiatry
in Munich, Germany, and at two psychiatric hospitals
in the Munich area (BKH Augsburg and Klinikum
Ingolstadt). The same inclusion and exclusion criteria
were applied in this study as the Radiant study. Patients
had to fulfil the diagnosis of recurrent major depressive
disorder of moderate or severe intensity using the SCAN
interview. Controls were selected randomly from a
Munich-based community and were screened for the
presence of anxiety or mood disorders using the Com-
posite International Diagnostic Screener (German ver-
sion) [19]. Only individuals without mood and anxiety
disorders were collected as controls. This study has been
described in more detail elsewhere [20]. Anthropometric
measures for patients and controls were taken at the
Max Planck Institute and associated studies sites by
trained technicians and study nurses [20].
This study was approved by the Ethics Committee of
the Ludwig Maximilian University, Munich, Germany
and written informed consent was obtained from all
participants.
PsyCoLaus study
A total of 2,993 participants (1,296 cases and 1,697 con-
trols) were recruited from a psychiatric sub-study(PsyCoLaus) of a community survey (CoLaus) carried
out in Lausanne, Switzerland. A DSM-IV diagnosis of
MDD was ascertained using the Diagnostic Interview for
Genetics Studies [21]. The control subjects never ful-
filled criteria for MDD. The PsyCoLaus study has been
described in more detail elsewhere [22]. Weight and
height were measured at the outpatient clinic at the
Centre Hospitalier Universitaire Vaudois [23].
The Ethics committee of the Faculty of Biology and
Medicine of the University of Lausanne approved the
study and informed consent was obtained from all
participants.
Selection of SNPs, genotyping, and quality control
procedure
In the discovery phase, all the participants in Radiant
were genotyped using the Illumina HumanHap610-
Quad BeadChips (Illuminia, Inc., San Diego, CA, USA)
by the Centre National de Génotypage as previously de-
scribed [24]. All DNA samples underwent stringent
quality control including exclusion if the sample geno-
type missing rate was >1%, or if abnormal heterozygosity
or unmatched sex assignment were observed. SNPs with
minor allele frequency <1% or showing departure from
the Hardy-Weinberg equilibrium (P <1 × 10−5) were ex-
cluded. Quality control was described in detail elsewhere
[24]. The risk alleles were defined as alleles associated
with increased risk of BMI. We derived a 32-SNP addi-
tive GRS from the SNPs reported by Speliotes et al. [9]
and Belsky et al. [25]. Of the 32 GRS SNPs, 14 were ex-
tracted from GWAS data after applying quality control,
and 13 were extracted using proxy SNPs with r2 > 0.9.
The remaining 5 SNPs, namely rs11847697, rs11083779,
rs11165643, rs7640855, and rs1475219, were derived
from the 1000 Genomes project imputed data. The qual-
ity measure of imputation for these SNPs was above 0.8.
The call rate for most SNPs was more than 96% except
for one SNP, rs1475219, which was approximately 91%.
The detailed information of the 32 SNPs is shown in
Table 1.
The GSK Munich study was used for replication.
Genotyping was performed using the Illumina Human-
Hap550 SNP Chip arrays. All SNPs with a call frequency
below 95% were excluded. The details were described
elsewhere [26]. The same criteria to construct the GRSs
was applied here; whenever possible, SNPs were ex-
tracted from the GWAS data after applying quality con-
trol, and the rest of the SNPs were extracted using proxy
SNPs.
Participants in the PsyCoLaus study were genotyped
using the Affymetrix 500 K SNP chip [22]. The genotype
was obtained via the BRLMM algorithm. The SNPs were
removed from the analysis based on gender inconsist-
ency, call rate less than 90%, and inconsistent duplicate
Table 1 Single nucleotide polymorphisms included in the genetic risk score in the RADIANT study
Chr Nearest gene SNP name Alleles BMI-increasing
allele
Frequency of
BMI-increasing allele
GWAS effect-size
for BMI
Call rate
1 NEGR1 rs2568958 A/G A 62.5% 0.13 99.95%
TNNI3K rs1514175 A/G A 42.3% 0.07 99.86%
PTBP2 rs11165643 C/T T 58.8% 0.06 99.07%
SEC16B rs10913469 C/T C 19.2% 0.22 100%
2 TMEM18 rs2867125 C/T C 82.9% 0.31 99.98%
ADCY3,RBJ rs10182181 A/G G 46.9% 0.14 99.40%
FANCL rs759250 A/G A 28.4% 0.1 100%
LRP1B rs6714473 C/T T 9.7% 0.09 99.85%
3 CADM2 rs7640855 A/G A 19.0% 0.1 96.83%
ETV5 rs7647305 C/T C 79.0% 0.14 99.93%
4 GNPDA2 rs12641981 C/T T 44.1% 0.18 100%
SLC39A8 rs13107325 C/T T 7.5% 0.19 99.91%
5 FLJ35779 rs253414 C/T T 66.4% 0.1 99.93%
ZNF608 rs6864049 A/G A 47.2% 0.07 100%
6 TFAP2B rs987237 A/G A 18.2% 0.13 100%
NUDT3 rs206936 A/G G 18.0% 0.06 95.99%
9 LRRN6C rs2183825 C/T C 32.9% 0.11 99.98%
11 STK33, RPL27A rs10840065 A/G A 51.6% 0.06 100%
BDNF rs6265 C/T C 79.8% 0.19 100%
MTCH2 rs10838738 A/G G 34.5% 0.06 100%
12 BCDIN3, FAIM2 rs7138803 A/G A 37.5% 0.12 100%
13 MTIF3 rs1475219 C/T C 20.4% 0.09 90.61%
14 PRKD1 rs11847697 C/T T 3.6% 0.17 96.87%
NRXN3 rs10146997 A/G G 21.9% 0.13 100%
15 MAP2K5 rs2241423 A/G G 77.2% 0.13 99.96%
16 GPRC5B rs12446632 A/G G 86.1% 0.17 99.93%
SH2B1 rs4788102 A/G A 39.0% 0.15 100%
FTO rs3751812 G/T T 41.0% 0.39 100%
18 MC4R rs921971 C/T C 26.6% 0.23 99.98%
19 KCTD15 rs29941 A/G G 68.3% 0.06 100%
ZC3H4, TMEM160 rs2303108 C/T C 71.4% 0.09 100%
QPCTL rs11083779 C/T T 95.8% 0.15 98.28%
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Construction of the unweighted and weighted GRS
To evaluate the combined effects of the 32 SNPs on
BMI, an additive model was used to construct both un-
weighted and weighted GRSs. The unweighted GRS
(uGRS) was calculated by summation of the number of
risk alleles across the 32 variants. The weighted GRS
(wGRS) was calculated by multiplying the number of
risk alleles at each locus (0, 1, 2) for the corresponding
effect sizes, in kg/m2 per allele, as reported by Spelioteset al. [9] and then summing the products. In order to re-
duce the bias caused by missing data, only the partici-
pants without any missing data were included in our
GRS analysis.Statistical analysis
Linear regression models using traditional risk factors
(age, sex, and principal components of ancestry) and
GRS were calculated to predict BMI. Since BMI did not
follow a normal distribution, a natural log-transformed
BMI was used for the analyses. The analyses were first
Hung et al. BMC Medicine  (2015) 13:86 Page 5 of 10performed in the whole sample and then separately in
the depressive cases and controls.
Binary logistic regression adjusted by age, sex, depres-
sion status and ancestry was used to predict probabilities
of obesity in each model. Receiver-operating characteris-
tics (ROC) curve analysis was conducted to calculate the
area under the curve (AUC) to evaluate the discrimin-
atory ability of each model. We first compared the dif-
ference between AUCs from models incorporating
traditional risk factors (age, sex, and ancestry) with and
without GRS. Then we compared the models comprising
GRS only and the models incorporating other risk fac-
tors. To correct for the possible presence of population
stratification, all analyses were adjusted for the first five
principal components of ancestry, which were calculated
with EIGENSOFT [27].
The analyses were performed first in the whole sam-
ple, and then separately in depressed patients and con-
trols. All data were analyzed using STATA version 12.1
(STATA Corp, Texas). Two-tailed value of P <0.05 were
considered significant.
Results
Discovery phase – Radiant study
Demographic characteristics
After excluding people with any missing genotypes, a
total of 2,521 participants (2,086 non-obese and 435
obese) were included in the analysis. There were no dif-
ferences in sex, age, and depression status between
included and excluded people (all P >0.05). The mean
age ± SD of participants was 43.9 ± 12.8 years (non-obese
43.2 ± 13.1, obese 47.3 ± 10.7, t = −6.08, P <0.0001) and
67.7% were female (72.9% female in obese and 66.6%0
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Figure 1 Distribution of weighted genetic risk score in RADIANT study.female in non-obese, χ2 = 6.50, P = 0.011). Obese people
were more likely to be depressed (90.3% vs. 72.0%, χ2 =
64.87, P <0.001).
The frequencies of uGRS and wGRS were approximately
within normal distribution (Figure 1). The mean uGRS,
the total number of risk alleles of 32 SNPs, was 29.5 ±
3.5 in obese and 28.6 ± 3.5 in non-obese participants
(t = −4.47, P <0.0001), whereas the mean wGRS was
slightly higher in obese compared to non-obese partici-
pants (4.14 ± 0.50 vs. 4.03 ± 0.53, t = −4.18, P <0.0001).
Principal component analysis was used to control for
population stratification. The top five principal compo-
nent scores were used to discriminate the subpopulation
of white Europeans. Principal component 1 (distinguishes
southeast Europe from northwest European ancestry) and
principal component 2 (distinguishes east Europe from
west Europe) were significantly associated with BMI and
were included as covariates.
Linear regression analyses with BMI as the outcome
variable
A base linear regression model including age, sex, de-
pression status, ancestry, and significant interaction be-
tween ancestry and age accounted for 8.29% of the
variance in log-transformed BMI. After adding weighted
GRS to the base model, there was improvement of fit
and an additional 1.27% of phenotypic variance of BMI
explained giving a total of 9.56% (Table 2). Using either
weighted or unweighted GRS made little difference for
the explained variance of BMI (9.56% vs. 9.58%). No
interaction between traditional covariates or between
GRS and traditional covariates were found (data not
shown). Although the interaction between depression4 5 6
netic Risk Score
Table 2 Linear regression models with BMI as the outcome variable
Study/sample Model F Adj. R2 Additional variance
explained by GRS
Radiant
Total Model 1: adjusted by age, sex, and depression 38.98 0.0829 1.27%
Model 2: model 1 + wGRS 39.16 0.0956
Depressed cases Model 1: adjusted by age and sex 17.85 0.0426 1.63%
Model 2: model 1 + wGRS 20.75 0.0589
Controls Model 1: adjusted by age and sex 11.71 0.0789 0.34%
Model 2: model 1 + wGRS 10.34 0.0823
GSK-Munich
Total Model 1: adjusted by age, sex, and depression 34.02 0.1056 0.53%
Model 2: model 1 + wGRS 29.80 0.1109
Depressed cases Model 1: adjusted by age and sex 8.02 0.0372 1.32%
Model 2: model 1 + wGRS 7.13 0.0504
Controls Model 1: adjusted by age and sex 25.66 0.1306 0.23%
Model 2: model 1 + wGRS 21.98 0.1329
PsyCoLaus
Total Model 1: adjusted by age, sex, and depression 40.20 0.0843 0.93%
Model 2: model 1 + wGRS 39.47 0.0936
Depressed cases Model 1: adjusted by age and sex 14.84 0.0605 1.09%
Model 2: model 1 + wGRS 15.15 0.0714
Controls Model 1: adjusted by age and sex 31.25 0.0970 0.77%
Model 2: model 1 + wGRS 29.21 0.1047
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of significance (ß = 0.27, s.e. = 0.02, P = 0.078), stratifying
by depression status with GRS incorporated in the
model explained an extra 1.63% of variance of BMI in
depressed patients but only explained an extra 0.34% of
variance of BMI in healthy controls.
Prediction of obesity
Logistic regression models were used to examine the re-
lationship between GRS and obesity in addition to age,
sex, ancestry, and depression status. The discriminative
power of the regression model was measured by the
AUC. The AUC was significantly higher in the model
combining all non-genetic risk factors (age, sex, ancestry,
and depression status) and genetic factors compared to
the model only applying non-genetic risk factors (AUC
increased from 0.69 to 0.71, χ2 = 9.83, P = 0.0017). We
further investigated whether GRS alone is able to dis-
criminate obesity or not. The AUC was only 0.58 (95%
CI, 0.55–0.61) while only including genetic risk score
and ancestry into the base regression model. However,
the AUC increased to 0.65 (95% CI, 0.62–0.68) after
adding traditional risk factors such as age and sex (χ2 =
21.46, P <0.0001). The AUC further increased to 0.71(95% CI, 0.68–0.73) on incorporating depression status
into the above model (χ2 = 32.33, P <0.0001; Figure 2).
Again, the unweighted GRS produced similar results as
the wGRS when incorporated into our regression model
(AUC increased from 0.58 to 0.65 to 0.70).
We used the same analysis stratifying by depression
status and found that, in depressed patients, the AUC
increased from 0.58 (95% CI, 0.55–0.61) to 0.61 (95% CI,
0.58–0.64; χ2 = 5.65, P = 0.0175) while in healthy controls
it remained at 0.67 (95% CI, 0.60–0.73; χ2 = 0.00, P =
0.98). No interaction was found between depression,
GRS, and obesity (OR = 1.08, s.e. = 0.36, P = 0.81).Replication phase – GSK Munich study
Demographic characteristics
A total of 1,679 participants (244 obese and 1,435 non-
obese) were included in this study. The mean age ± SD
was 51.49 ± 13.50 years (53.29 ± 11.51 for obese and
51.19 ± 13.80 for non-obese, P = 0.01). There was no sex
difference between obese and non-obese patients
(64.75% obese and 67.24% non-obese patients were fe-
male, P = 0.44). Obese people were more likely to be de-
pressed (64.75% vs. 46.27%, P <0.001).
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Figure 2 Receiver operating characteristic curves for models predicting obesity in the discovery phase. The AUC for the full model combining
depression status, age, sex, and GRS (×3) is significantly greater than AUC for the model combining age, sex, and GRS (×2), which in turn is
significantly greater than AUC for the base model with only GRS (×1).
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variable
Linear regression models to predict BMI suggested
the wGRS accounts for 0.63% of the variance in log-
transformed BMI. While stratifying by depression status,
we found wGRS explained an extra 1.32% of phenotypic
variance of BMI in depressed patients but only accounted
for 0.23% of variance in healthy controls (Table 2).
No significant interaction was found between depres-
sion and GRS on BMI (ß = 0.25, s.e. = 0.01, P = 0.18).Prediction of obesity
Logistic regression models were used to examine the rela-
tionship between GRS and obesity in addition to age, sex,
ancestry, and depression status. The AUC was approxi-
mately 0.59 (95% CI, 0.55–0.63) while only including gen-
etic risk score and ancestry into the base regression
model. The AUC increased to 0.64 (95% CI, 0.60–0.68)
while adding traditional risk factors such as age and sex
(χ2 = 8.21, P = 0.004). The AUC further increased to 0.69
(95% CI, 0.66–0.73) while incorporating depression status
into the above model (χ2 = 10.67, P = 0.001). Stratified ana-
lyses by depression status showed that using wGRS to dis-
criminate obesity was statistically significant in depressed
patients (AUC increased from 0.53 (95% CI, 0.48–0.58) to
0.58 (95% CI, 0.53–0.63), χ2 = 4.19, P = 0.041) but not in
healthy controls (AUC remained at 0.66 (95% CI, 0.60–
0.72), χ2 = 0.34, P = 0.56).
No significant interaction was found between depres-
sion and GRS on obesity (OR = 1.38, s.e. = 0.39, P = 0.26).PsyCoLaus study
Demographic characteristics
Overall, 2,993 subjects (409 obese and 2,584 non-obese)
were included in PsyCoLaus study. The mean age ± SD
was 50.19 ± 8.84 years (52.94 ± 8.80 for obese and 49.76 ±
8.77 for non-obese, P <0.0001). There were no sex differ-
ences between obese and non-obese patients (49.87% of
obese and 53.44% of non-obese people were female,
P = 0.18). Obese people and non-obese people had equal
depression rates (40.83% vs. 43.69%, P = 0.28).
Linear regression analyses with BMI as the outcome
variable
Linear regression analysis to predict BMI suggested the
wGRS accounts for 0.90% of the variance in log-
transformed BMI. While stratifying by depression status,
we found that wGRS explained an extra 1.09% of pheno-
typic variance of BMI in depressed patients but only
accounted for 0.77% of variance of BMI in healthy con-
trols (Table 2).
No significant interaction was found between depres-
sion and GRS on BMI (ß = 0.09, s.e. = 0.01, P = 0.52).
Prediction of obesity
Again, logistic regression models were used to examine
the relationship between GRS and obesity in addition to
age, sex, ancestry, and depression status. The AUC was
approximately 0.56 (95% CI, 0.53–0.58) while only in-
cluding GRS and ancestry into the base regression
model. The AUC increased to 0.62 (95% CI, 0.59–0.65)
while adding traditional risk factors such as age and sex
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CI, 0.59–0.65) while incorporating depression status into
the above model (χ2 = 0.11, P = 0.74). Stratified analyses
by depression status showed that using wGRS to dis-
criminate obesity was not statistically significant neither
in depressed patients (AUC increased from 0.61 (95%
CI, 0.56–0.66) to 0.63 (95% CI, 0.58–0.67), χ2 = 3.66, P =
0.0558) nor in healthy controls (AUC increased from
0.61 (95% CI, 0.57–0.65) to 0.62 (95% CI, 0.59–0.66),
χ2 = 2.66, P = 0.1).
No significant interaction was found between depres-
sion and GRS on obesity (OR = 0.98, s.e. = 0.21, P = 0.94).
Discussion
In this study, we developed both weighted and un-
weighted GRS, including 32 well-established risk loci
from a recent meta-analysis of GWAS on BMI [9]. We
aimed to investigate whether these GRSs are associated
with BMI and predict obesity.
Prediction of BMI
Both uGRS and wGRS were associated with BMI
(P <0.0001) and accounted for 1.27%, 0.63%, and 0.90%
of phenotypic variance of BMI in Radiant, GSK Munich,
and PsyCoLaus studies, respectively, and there was little
difference in explained variance of BMI in each study. For
each unit increase in uGRS, which is equal to one
additional risk allele, BMI increased by approximately
0.175 kg/m2. Our overall result was thus in keeping with a
previous study [9] using the same method to construct a
GRS for BMI, but which did not take into account the re-
lationship between BMI and depression.
Our results suggest that GRS explained more phenotypic
variance of BMI in depressed patients than in healthy con-
trols, although the interaction analyses were suggestive
(Radiant) but not significant (GSK Munich and PsyCo-
Laus), this could reflect the fact that conventional levels of
significance for interaction are often difficult to detect
when the outcome variable has been log transformed.
Interestingly, the case/control difference in the effect of
GRS was more prominent when depression was diagnosed
in clinical settings (RADIANT and GSK Munich studies)
than in a community study (PsyCoLaus study).
Prediction of obesity
We further explored the utility of a GRS approach using
ROC analysis to compare the discriminatory ability of
predictors of obesity. Conventionally, it is accepted that
the AUC in a ROC analysis should be >0.8 to be of clin-
ical value for screening. During the discovery phase,
AUC fell short of this threshold but combining genetic
factors and non-genetic factors proved better than using
GRS alone in the prediction of obesity (with the AUC in-
creasing from 0.69 to 0.71). In the replication phase,findings were similar except that depression had a small
and non-significant association with obesity in the Psy-
CoLaus study, which could reflect the fact that PsyCo-
Laus was a community-based study with less severe
cases of MDD than the clinically ascertained RADIANT
and Munich GSK studies. Our results suggest that GRS
might improve obesity prediction in depressed patients
compared to controls.
In other respects, the results were similar to previous
studies, which used only genome wide significant genetic
variants to construct a GRS [11], in finding that the
optimum AUC was obtained by combining GRS and
non-genetic risk factors. A significant novel feature of
the present study was that combining these factors with
depression status further improves the prediction of
obesity. This is in keeping with the association between
obesity and MDD that has been found in either the
general population or clinical settings [4,5,28]. Although
the relationship between these two diseases may be bi-
directional [5], our own recent analyses using a Mendelian
Randomization approach [29] do not support a direction
of cause from high BMI to depression. In addition, the fact
that GRS has a larger effect on BMI and obesity in
depressed patients, especially clinically severe depression,
might reflect the importance of genetic effects on the
association between obesity and clinically significant
depression.Limitations
There are certainly some limitations that should be
mentioned. First, we only selected the risk loci that
reached genome-wide levels of significance. It is highly
probable that there are additional as yet to be identified
loci that will emerge when even larger sample sizes are
included in GWAS. Second, since the established com-
mon variants from GWAS explain only a small propor-
tion of the variation in BMI, future studies should
include rare variants with larger effects and copy num-
ber variants to construct future GRS. In addition, gene-
gene interactions and gene-environment interactions
should be taken into account as well to maximize the
obesity prediction ability of GRS. For example, our
group [10] has found that depression status moderates
the effect of FTO gene on BMI (although we did not find
evidence of interaction between depression and GRS in
the current study). Third, the 32 BMI loci used to
construct the GRS were identified in GWAS of white
European origin. The allele frequencies and their effect
size may be different from non-European populations
and the results should probably not be generalized to
other ethnicities. Furthermore, the present study is a
cross sectional study and cannot therefore take into ac-
count BMI fluctuations across the life span.
Hung et al. BMC Medicine  (2015) 13:86 Page 9 of 10A further minor drawback is that PsyCoLaus is a sub-
set of the CoLaus study, which was one of the 46 studies
from which the GRS was derived [9], and therefore can-
not, on its own, provide independent estimation of the
risk score effect.
Conclusions
In summary, we found that either a wGRS or a uGRS
based on 32 well-established risk loci were significantly
associated with BMI. Although GRS on its own ex-
plained only a small amount of variance of BMI, a sig-
nificant novel feature of this study is that including non-
genetic risk factors together with GRS and depression
came close to the conventional threshold for clinical
utility used in ROC analysis and improves the prediction
of obesity.
Our results suggest that the GRS might predict obesity
better in depressed patients than in healthy controls. This
has potential clinical implications as well as implications
for future research directions in exploring the links be-
tween depression and obesity-associated disorders.
While it is likely that future genome-wide studies with
very large samples will detect variants other than the
common ones, it seems probable that a combination of
non-genetic information will still be needed to optimize
the prediction of obesity.
Additional file
Additional file 1: List of institutions where the ethical committees
gave approval for the Radiant study.
Abbreviations
AUC: Area under the curve; BMI: Body mass index; DeCC: Depression case–
control study; DeNT: Depression network study; FTO: Fat mass and obesity
associated gene; GENDEP: Genome-based therapeutic drugs for depression;
GRS: Genetic risk score; GWAS: Genome-wide association studies;
MDD: Major depressive disorder; ROC: Receiver operating characteristic;
SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SNP: Single
nucleotide polymorphism; uGRS: Unweighted genetic risk score;
wGRS: Weighted genetic risk score.
Competing interests
AEF and PM have received consultancy fees and honoraria for participating
in expert panels for pharmaceutical companies including GlaxoSmithKline.
PM has received speaker’s fees from Pfizer. FH is cofounder of the biotech
company HolsboerMaschmeyerNeuroChemie GmbH (HMNC GmbH) in
Germany. WM is member of the Advisory Board or has received speaker fees
from Eli Lilly and Lundbeck. MP is part of the advisory boards for Eli Lilly and
Lundbeck. All other authors declare no competing interests. This study was
funded by the Medical Research Council, UK. GlaxoSmithKline (G0701420)
funded the DeNT study and were co-funders with the Medical Research
Centre for the GWAS of the whole sample. The GENDEP study was funded
by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-
2003-503428. This study presents independent research [part-] funded by
the National Institute for Health Research (NIHR) Biomedical Research
Centre at South London and Maudsley NHS Foundation Trust and King’s
College London. The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR, or the Department of Health. The
CoLaus/PsyCoLaus was funded by four grants from the Swiss National
Science Foundation (#32003B-105993, #32003B-118308, #33CSC0-122661,and #139468), the Faculty of Biology and Medicine of Lausanne, and two
grants from GlaxoSmithKline Clinical Genetics.
Authors’ contributions
PM, MR, and CH participated in the design of the study. CH performed
statistical analyses and wrote the first draft of the manuscript. DC, TC, and
CW helped with the statistical analyses and extraction of the SNPs from the
GWAS data. SB, ZK, and BM contributed to the analyses. PM and MR lead the
study and made critical revisions to the report. GB, PM, and MR supervised
the statistical analyses. SK, NC, MG, FH, LJ, IJ, AK, SL, WM, OM, MO, JR, MR, RU,
PV, GW, AF, MP, and PM participated in the collection of clinical and
phenotype data. IC contributed to the coordination of genotyping for the
Radiant study. All authors were involved in drafting the manuscript or
revising it critically for important intellectual content, and approved the final
version of the manuscript to be published.
Acknowledgements
The authors would like to thank those who agreed to participate in the
studies and the many colleagues who contributed to collection and
phenotypic characterization of the clinical samples, as well as to genotyping
and statistical analyses.
Author details
1MRC SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s
College London Box PO82, De Crespigny Park, Denmark Hill London SE5 8AF,
UK. 2Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital
and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
3National Institute for Health Research Biomedical Research Centre for
Mental Health at the Maudsley and Institute of Psychiatry, King’s College
London London, UK. 4Max-Planck-Institute of Psychiatry Kraepelinstraße 2
80804 Munich, Germany. 5Institute of Social and Preventive Medicine
(IUMSP), Centre Hospitalier, Universitaire Vaudois (CHUV), 1010 Lausanne,
Switzerland. 6Swiss Institute of Bioinformatics Lausanne 1015, Switzerland.
7MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University,
Hadyn Ellis Building Maindy Road Cardiff CF24 4HQ, UK. 8Department of
Psychiatry, Trinity Centre for Health Sciences Dublin 8, Ireland. 9Department
of Psychiatry, School of Clinical and Experimental Medicine, University of
Birmingham Birmingham B15 2TT, UK. 10Barts and The London School of
Medicine and Dentistry, Queen Mary’s University of London London E1 2AD,
UK. 11Department of Psychiatry, University of Bonn 53127 Bonn, Germany.
12Research Department P, Aarhus University Hospital Skovagervej 2 DK-8240
Risskov, Denmark. 13MRC Centre for Neuropsychiatric Genetics and
Genomics, Department of Psychological Medicine and Neurology, School of
Medicine, Cardiff University Henry Wellcome Building, Heath Park Cardiff
CF14 4XN, UK. 14Department of Psychiatry, Washington University School of
Medicine St Louis, MO 63130, USA. 15Central Institute of Mental Health 68159
Mannheim, Germany. 16Department of Psychiatry, Dalhousie University,
Halifax Nova Scotia, NS B3H 3J5, Canada. 17Division of Internal Medicine,
CHUV Rue du Bugnon 21, 1011 Lausanne, Switzerland. 18Department of
Medical and Molecular Genetics, School of Medicine, King’s College London
8th Floor, Tower Wing, Guys Hospital London SE1 9RT, UK. 19Department of
Psychiatry, Lausanne University Hospital 1008 Prilly-Lausanne, Switzerland.
20CIBERSAM-University of Granada and Institute of Neurosciences Federico
Olóriz, Centro de Investigación Biomédica, University of Granada Avda del
Conocimiento s/n, 18100 Armilla Granada, Spain. 21Instituto de Investigación
Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad
de Granada 18012, C/ Dr. Azpitarte, 4, 18012 Granada, Spain.
Received: 5 December 2014 Accepted: 24 March 2015
References
1. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of
hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity:
findings from the National Health and Nutrition Examination Survey, 1999
to 2004. J Am Coll Surg. 2008;207:928–34.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in
obesity among US adults, 1999–2008. JAMA. 2010;303:235–41.
3. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and
economic burden of the projected obesity trends in the USA and the UK.
Lancet. 2011;378:815–25.
Hung et al. BMC Medicine  (2015) 13:86 Page 10 of 104. Farmer A, Korszun A, Owen MJ, Craddock N, Jones L, Jones I, et al. Medical
disorders in people with recurrent depression. Br J Psychiatry. 2008;192:351–5.
5. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, et al.
Overweight, obesity, and depression: a systematic review and meta-analysis
of longitudinal studies. Arch Gen Psychiatry. 2010;67:220.
6. Maes HHM, Neale MC, Eaves LJ. Genetic and environmental factors in
relative body weight and human adiposity. Behav Genet. 1997;27:325–51.
7. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P,
Helgadottir A, et al. Genome-wide association yields new sequence variants
at seven loci that associate with measures of obesity. Nat Genet.
2008;41:18–24.
8. Willer CJ, Speliotes EK, Loos RJF, Li S, Lindgren CM, Heid IM, et al. Six new
loci associated with body mass index highlight a neuronal influence on
body weight regulation. Nat Genet. 2008;41:25–34.
9. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU,
et al. Association analyses of 249,796 individuals reveal 18 new loci
associated with body mass index. Nat Genet. 2010;42:937–48.
10. Rivera M, Cohen-Woods S, Kapur K, Breen G, Ng M, Butler AW, et al. Depres-
sive disorder moderates the effect of the FTO gene on body mass index.
Mol Psychiatry. 2012;17:604–11.
11. Sandholt CH, Sparsø T, Grarup N, Albrechtsen A, Almind K, Hansen L, et al.
Combined analyses of 20 common obesity susceptibility variants. Diabetes.
2010;59:1667–73.
12. Peterson RE, Maes HH, Holmans P, Sanders AR, Levinson DF, Shi J, et al.
Genetic risk sum score comprised of common polygenic variation is
associated with body mass index. Hum Genet. 2011;129:221–30.
13. Li S, Zhao JH, Luan J, Luben RN, Rodwell SA, Khaw KT, et al. Cumulative
effects and predictive value of common obesity-susceptibility variants
identified by genome-wide association studies. Am J Clin Nutr. 2010;91:184–90.
14. Farmer A, Breen G, Brewster S, Craddock N, Gill M, Korszun A, et al. The
Depression Network (DeNT) Study: methodology and sociodemographic
characteristics of the first 470 affected sibling pairs from a large multi-site
linkage genetic study. BMC Psychiatry. 2004;4:42.
15. Cohen-Woods S, Gaysina D, Craddock N, Farmer A, Gray J, Gunasinghe C,
et al. Depression Case Control (DeCC) Study fails to support involvement of
the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major
depressive disorder. Hum Mol Genet. 2009;18:1504–9.
16. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al.
Genetic predictors of response to antidepressants in the GENDEP project.
Pharmacogenomics J. 2009;9:225–33.
17. Wing JK, Babor T, Brugha T, Burke J, Cooper J, Giel R, et al. SCAN: schedules
for clinical assessment in neuropsychiatry. Arch Gen Psychiatry. 1990;47:589.
18. McGuffin P, Katz R, Aldrich J. Past and present state examination: the
assessment of ‘lifetime ever’ psychopathology. Psychol Med. 1986;16:461–5.
19. Wittchen HU, Höfler M, Gander F, Pfister H, Storz S, Üstün B, et al. Screening
for mental disorders: performance of the Composite International
Diagnostic–Screener (CID–S). Int J Methods Psychiatr Res. 1999;8:59–70.
20. Lucae S, Salyakina D, Barden N, Harvey M, Gagné B, Labbé M, et al. P2RX7, a
gene coding for a purinergic ligand-gated ion channel, is associated with
major depressive disorder. Hum Mol Genet. 2006;15:2438–45.
21. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG,
Harkavy-Friedman J, et al. Diagnostic interview for genetic studies: rationale,
unique features, and training. Arch Gen Psychiatry. 1994;51:849–59.
22. Preisig M, Waeber G, Vollenweider P, Bovet P, Rothen S, Vandeleur C, et al.
The PsyCoLaus study: methodology and characteristics of the sample of a
population-based survey on psychiatric disorders and their association with
genetic and cardiovascular risk factors. BMC Psychiatry. 2009;9:9.
23. Firmann M, Mayor V, Vidal PM, Bochud M, Pécoud A, Hayoz D, et al. The
CoLaus study: a population-based study to investigate the epidemiology
and genetic determinants of cardiovascular risk factors and metabolic
syndrome. BMC Cardiovasc Disord. 2008;8:6.
24. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al.
Genome-wide association study of major recurrent depression in the UK
population. Am J Psychiatr. 2010;167:949–57.
25. Belsky DW, Moffitt TE, Houts R, Bennett GG, Biddle AK, Blumenthal JA, et al.
Polygenic risk, rapid childhood growth, and the development of obesity
evidence from a 4-decade longitudinal study. Arch Pediatr Adolesc Med.
2012;166:515–21.
26. Muglia P, Tozzi F, Galwey N, Francks C, Upmanyu R, Kong X, et al. Genome-
wide association study of recurrent major depressive disorder in two
European case–control cohorts. Mol Psychiatry. 2010;15:589–601.27. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D.
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet. 2006;38:904–9.
28. Zhao G, Ford E, Dhingra S, Li C, Strine T, Mokdad A. Depression and anxiety
among US adults: associations with body mass index. Int J Obes (Lond).
2009;33:257–66.
29. Hung C-F, Rivera M, Craddock N, Owen MJ, Gill M, Korszun A, et al. Relationship
between obesity and the risk of clinically significant depression: Mendelian
randomisation study. Br J Psychiatr. 2014;205:24–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
